AURA Insider Trading

Insider Ownership Percentage: 5.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,068,595.57

Aura Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Aura Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Aura Biosciences Share Price & Price History

Current Price: $5.30
Price Change: Price Increase of +0.33 (6.64%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for AURA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$5.30Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Aura Biosciences (NASDAQ:AURA)

96.75% of Aura Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AURA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$51kbought$51ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal InflowsTotal Outflows
Aura Biosciences logo
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More on Aura Biosciences

Today's Range

Now: $5.30
Low: $4.94
High: $5.32

50 Day Range

MA: $6.96
Low: $4.97
High: $8.21

52 Week Range

Now: $5.30
Low: $4.84
High: $12.38

Volume

195,986 shs

Average Volume

199,817 shs

Market Capitalization

$266.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Who are the company insiders with the largest holdings of Aura Biosciences?

Aura Biosciences' top insider investors include:
  1. Matrix Capital Management Comp (Major Shareholder)
  2. Los Pinos Elisabet De (Insider)
  3. Janet Jill Hopkins (Insider)
  4. Mark Plavsic (CTO)
  5. Julie B Feder (CFO)
  6. David Michael Johnson (Director)
  7. Amy Elazzouzi (SVP)
  8. Amy Elazzouzi (VP)
Learn More about top insider investors at Aura Biosciences.

Who are the major institutional investors of Aura Biosciences?

Aura Biosciences' top institutional investors include:
  1. Rhumbline Advisers — 0.13%
  2. GAMMA Investing LLC — 0.02%
Learn More about top institutional investors of Aura Biosciences stock.

Which institutional investors are selling Aura Biosciences stock?

During the previous quarter, AURA stock was sold by these institutional investors:
  1. Rhumbline Advisers
In the last year, company insiders that have sold Aura Biosciences company stock include:
  1. Matrix Capital Management Comp (Major Shareholder)
  2. Los Pinos Elisabet De (Insider)
  3. Janet Jill Hopkins (Insider)
  4. Mark Plavsic (CTO)
  5. Julie B Feder (CFO)
  6. David Michael Johnson (Director)
Learn More investors selling Aura Biosciences stock.

Which institutional investors are buying Aura Biosciences stock?

During the last quarter, AURA stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
During the previous year, these company insiders have bought Aura Biosciences stock:
  1. Matrix Capital Management Comp (Major Shareholder)
  2. Los Pinos Elisabet De (Insider)
Learn More investors buying Aura Biosciences stock.